相关实验视频

Updated: Jun 25, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

顺序 (第一到第三代) EGFR-TKI治疗对NSCLC患者纠正的QT间隔的影响

Tian Gan¹, Jindong Chen¹, Hao Wang¹

¹Department of Cardiology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Frontiers in oncology

|May 22, 2024

概括

连续的表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 治疗在非小细胞肺癌患者中延长了纠正的QT间隔 (QTc). 进一步的QTc延长发生在先进一代EGFR-TKIs中,心周溢血和低是关键预测因素.

科学领域:

心脏病学心脏病学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

顺序表皮生长因子受体氨酸激酶抑制剂 (EGFR-TKI) 疗法是非小细胞肺癌 (NSCLC) 的标准治疗方法.
顺序EGFR-TKI治疗对心脏电生理学的影响,特别是纠正的QT间隔 (QTc),需要进行彻底评估.

研究的目的:

评估顺序 (第一到第三代) EGFR-TKI治疗对NSCLC患者纠正的QT间隔 (QTc) 的影响.
在顺序EGFR-TKI治疗期间确定QTc延长的预测因子.

主要方法:

对228名用顺序EGFR-TKI治疗的NSCLC患者的医疗记录进行了回顾性审查.
分析心电图 (ECG) 数据,包括心率 (HR),QT间隔和QTc.
后勤回归以确定QTc延长的独立预测因子.

主要成果:

第一代EGFR-TKI和第三代EGFR-TKI都延长了QT间隔.
在第一代EGFR-TKI治疗后,观察到QTc和HR的显著增加.
随着连续的第三代EGFR-TKIs,随着HR升高,出现了进一步的QTc延长和HR增加,随着HR升高,出现了矛盾的QT间隔变化.
周心输液和低血清水平被确定为额外的QTc延长的独立预测因素.

结论:

连续的EGFR-TKI治疗,特别是第三代药物,导致NSCLC患者的QTc延长显著.
在EGFR-TKI治疗期间心率升高与矛盾的QT间隔变化和进一步的QTc延长有关.
监测心周输液和血清水平对于在顺序EGFR-TKI治疗期间管理QTc延长至关重要.

关键词:

晚期的肺癌是什么?纠正的 QT 间隔.皮肤生长因子受体-铁氨酸激酶抑制剂非小细胞肺癌的肺癌.风险因素的风险因素是什么

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...